In a 3-year industry sponsored trial, there was a nonsignificant trend for regular treatment with both a LABA and a LABA/ICS combination to reduce mortality. 102 In a 4-year industry sponsored trial there was a nonsignificant trend for regular treatment with a LAMA to reduce mortality. 103 A pooled safety analysis compiled from the randomized, double-blind, placebo-co
1
—
—